See more : Deutsche Post AG (DHL.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Korro Bio, Inc. (KRRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Korro Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Simbhaoli Sugars Limited (SIMBHALS.BO) Income Statement Analysis – Financial Results
- Republic Services, Inc. (0KW1.L) Income Statement Analysis – Financial Results
- BRP Inc. (DOO.TO) Income Statement Analysis – Financial Results
- Imed Infinity Medical-Limited Partnership (IMED.TA) Income Statement Analysis – Financial Results
- HSBC Holdings plc (HSBA.L) Income Statement Analysis – Financial Results
Korro Bio, Inc. (KRRO)
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Cost of Revenue | 3.63M | 2.51M | 3.84M | 1.58M | 16.81M | 654.00K | 531.00K |
| Gross Profit | -3.63M | -2.51M | 10.23M | 35.40M | 12.13M | -654.00K | -531.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 72.70% | 95.73% | 41.92% | 0.00% | 0.00% |
| Research & Development | 57.25M | 42.20M | 23.81M | 36.66M | 18.33M | 11.58M | 11.79M |
| General & Administrative | 27.28M | 16.80M | 11.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.28M | 16.80M | 11.69M | 26.30M | 14.48M | 6.71M | 3.99M |
| Other Expenses | 0.00 | 976.00K | 13.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 84.53M | 59.00M | 35.49M | 62.95M | 32.81M | 18.29M | 15.78M |
| Cost & Expenses | 84.53M | 59.00M | 35.49M | 64.53M | 49.62M | 18.94M | 16.31M |
| Interest Income | 0.00 | 947.00K | 0.00 | 994.00K | 1.78M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 118.00K | 0.00 | 0.00 | 0.00 | 106.00K | 174.00K |
| Depreciation & Amortization | 3.63M | 2.51M | 3.84M | 1.58M | 813.00K | 654.00K | 531.00K |
| EBITDA | -80.90M | -56.49M | -33.90M | -24.90M | -17.93M | -18.41M | -19.53M |
| EBITDA Ratio | 0.00% | 0.00% | -240.97% | -70.22% | -68.62% | 0.00% | 0.00% |
| Operating Income | -84.53M | -59.00M | -35.49M | -27.55M | -20.68M | -18.94M | -16.31M |
| Operating Income Ratio | 0.00% | 0.00% | -252.30% | -74.49% | -71.42% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.39M | 976.00K | 13.54M | 1.07M | 1.93M | -224.00K | -3.93M |
| Income Before Tax | -81.15M | -58.02M | -21.96M | -26.48M | -18.75M | -19.17M | -20.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | -156.08% | -71.59% | -64.76% | 0.00% | 0.00% |
| Income Tax Expense | 27.00K | 10.00K | 2.00K | 35.00K | 0.00 | 0.00 | 1.00 |
| Net Income | -81.17M | -58.03M | -21.96M | -26.51M | -18.75M | -19.17M | -20.24M |
| Net Income Ratio | 0.00% | 0.00% | -156.09% | -71.68% | -64.76% | 0.00% | 0.00% |
| EPS | -53.09 | -227.58 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| EPS Diluted | -53.08 | -227.42 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| Weighted Avg Shares Out | 1.53M | 255.00K | 4.45M | 645.06K | 616.89K | 627.09K | 627.09K |
| Weighted Avg Shares Out (Dil) | 1.53M | 255.17K | 4.45M | 645.06K | 616.89K | 627.09K | 627.09K |
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the...
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024
Korro Announces $70 Million Private Placement
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that...
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, Ph.D., will participate, present,...
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, today reported financial results for the full...
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy,...
Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 86.9% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
Korro to Present at the TD Cowen 44th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, on...
Best Momentum Stocks to Buy for February 16th
Teaser: ECL, CDNS and KRRO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 16, 2023.
New Strong Buy Stocks for February 16th
CDNS, ECL, FMX, KRRO and RMR have been added to the Zacks Rank #1 (Strong Buy) List on February 16, 2024.
Source: https://incomestatements.info
Category: Stock Reports